GE Healthcare doubles AI with new product launches, partnerships with Optellum and Cambridge

As GE prepares to split its healthcare business into a separate entity, the future autonomous company continues its quest to develop a wide range of artificial intelligence tools designed to overhaul and reorganize existing hospital practices.

At the annual meeting of the Radiological Society of North America, GE Healthcare not only unveiled dozens of new digital solutions to improve patient screening, diagnosis, treatment, and monitoring, but also paid close attention to several AI-based technologies the company has launched in recent times. month.

The most recent of these is Critical Care Suite 2.0, an AI platform integrated with a mobile X-ray machine to automatically calculate measurements during analyzes, sort cases and oversee quality controls. AI algorithms received historic clearance from the FDA this month, when one of the following AI algorithms became the first approved by the agency to help clinicians assess endotracheal tube locations. .

GE also put forward its Allia platform, which acts as an AI-powered assistant throughout image-guided therapy procedures. The system works around clinicians to automatically position a laser-guided robotic arm and uses augmented reality to improve its guidance throughout a procedure. It also keeps track of each clinician’s technology preferences, allowing the imaging suite to be immediately reset and personalized to their needs each time they access it.

RELATED: GE Healthcare to Become a Stand-Alone Company After Conglomerate Completes Three-Way Split

While it already has a wide range of AI systems and devices, GE also continues to develop new tools that use AI and machine learning to accelerate diagnostics and treatment.

A new project announced last week will see GE partner with Optellum to improve early detection of lung cancer. Optellum developed the Virtual Nodule Clinic, which uses AI to predict the likelihood that an identified lung nodule is malignant, simultaneously eliminating unnecessary biopsies for benign nodules and speeding up treatment of cancerous nodules.

Through their collaboration, GE will work with Optellum to integrate the FDA-approved system into GE’s range of imaging tools, including CT scanners and Image Archiving and Communication Systems, or PACS, as well. as its own Edison AI platform.

“The integration of imaging data and medical devices from the Edison platform with AI-based solutions such as that offered by the Optellum Virtual Nodule Clinic has the potential to streamline the workflows of clinicians and clinicians. advancing our goal of creating precision healthcare – taking the right action at the right time for every patient, at scale, as widely accessible as possible, ”said Ben Newton, Ph.D., chief executive officer of oncology solutions from GE Healthcare.

RELATED: GE Healthcare and Sophia Genetics Combine Cancer Care Using Patient-Treatment Matching Tools

Meanwhile, in another partnership announced this week, GE will partner with the University of Cambridge and Cambridge University Hospitals to develop a machine-learning-based tool that will compile data from patients with cancer in a centralized location for easier access by their care teams.

The solution will bring together clinical, imaging and genomic data in a single interface that will be made available to oncologists, surgeons, radiologists, pathologists and others, who can then use the data to collaborate on writing the most effective treatment plan. effective for each patient and more closely monitor their progress throughout the plan.

To begin with, the partners will design the system around collecting data for ovarian cancer patients at Cambridge hospitals. From there it will be rolled out to ovarian cancer patients across the UK and beyond, after which, if found to be effective, GE and Cambridge plan to make it available for use. patients with breast and kidney cancer.

Comments are closed.